Patients, n(%) | |
---|---|
Bacterial culture results | 36(43.4%) |
Sputum bacteria culture positive | 22(26.5%) |
Blood bacteria culture positive | 9(10.8%) |
Urine bacteria culture positive | 5(6.2%) |
Fecal bacteria culture positive | 0 |
Complications | |
Acute respiratory failure | 71(85.5%) |
Acute myocardial infarction | 6(7.2%) |
Heart failure | 37(44.6%) |
Acute liver injury | 9(10.8%) |
Acute kidney injury | 22(26.5%) |
Gastrointestinal bleeding | 16(19.2%) |
Sepsis | 69(83.1%) |
Shock | 33(39.8%) |
Treatments | |
Antiviral therapy | 83(100%) |
Monotherapy | |
Abidole | 6(7.2%) |
Combination therapyAbidole | |
Abidole/ Oseltamivir | 57(68.7%) |
Abidole/ Ribavirin | 16(19.3%) |
Abidole/ Lopinavir and Ritonavir | 3(3.6%) |
Abidole/ Oseltamivir/ Lopinavir and Ritonavir | 1(1.2%%) |
Antifungal therapy | 2(2.4%%) |
Antibiotic therapy | 81(97.6%) |
Penicillins | 24(28.9%) |
Cephalosporins | 52(62.7%) |
Quinolone | 35(42.2%) |
Vancomycin | 11(13.3%) |
Glucocorticoid therapy | 54(65.1%) |
Intravenous immunoglobulin therapy | 39(47.0%) |
CRRT | 6(7.3%) |
Invasive mechanical ventilation | 20(24.1%) |
Non-invasive mechanical ventilation | 51(61.4%) |
High flow nasal cannula | 12(14.5%) |
ECMO | 1(1.2%) |